Cited by 2,575Multiple Myeloma Research and TreatmentsBone health and treatmentsChronic Lymphocytic Leukemia Research

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Open access

Singhal, Seema, Mehta, Jayesh, Desikan, Raman, Ayers, Dan, Roberson, Paula, Eddlemon, Paul, Munshi, Nikhil, Anaissie, Elias, Wilson, Carla, Dhodapkar, Madhav, Zeldis, Jerome, Siegel, David, Crowley, John, Barlogie, Bart·1999·New England Journal of Medicine

DOI 10.1056/nejm199911183412102

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone marrow vascularity imparts a poor prognosis in myeloma, we evaluated the efficacy of thalidomide, which has antiangiogenic properties, in patients with refractory disease. METHODS: Eighty-four previously treated patients with refractory myeloma (76 with a relapse after high-dose chemotherapy) received oral thalidomide as a single agent for a median of 80 days (range, 2 to 465). The starting dose was 200 mg daily, and the dose was increased by 200 mg every two weeks until it reached 800 mg per day. Response was assessed on the basis of a reduction of the myeloma protein in serum or Bence Jones protein in urine that lasted for at least six weeks. RESULTS: The serum or urine levels of paraprotein were reduced by at least 90 percent in eight patients (two had a complete remission), at least 75 percent in six patients, at least 50 percent in seven patients, and at least 25 percent in six patients, for a total rate of response of 32 percent. Reductions in the paraprotein levels were apparent within two months in 78 percent of the patients with a response and were associated with decreased numbers of plasma cells in bone marrow and increased hemoglobin levels. The microvascular density of bone marrow did not change significantly in patients with a response. At least one third of the patients had mild or moderate constipation, weakness or fatigue, or somnolence. More severe adverse effects were infrequent (occurring in less than 10 percent of patients), and hematologic effects were rare. As of the most recent follow-up, 36 patients had died (30 with no response and 6 with a response). After 12 months of follow-up, Kaplan-Meier estimates of the mean (+/-SE) rates of event-free survival and overall survival for all patients were 22+/-5 percent and 58+/-5 percent, respectively. CONCLUSIONS: Thalidomide is active against advanced myeloma. It can induce marked and durable responses in some patients with multiple myeloma, including those who relapse after high-dose chemotherapy.

Integrity signals

Registry

Crossref · 10.1056/nejm199911183412102

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Bone marrow transplant
Szer, J. (1999) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,373
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Unbalanced repeated-measures models with structured covariance matrices.
Jennrich, R., & Schluchter, M. (1986) · Biometrics · doi:10.2307/2530695 · Cited by 1,382
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.
Sampaio, E. P., Sarno, E. N., Gallily, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.699 · Cited by 1,191

Show all 35 references

Research works printed but not linked: 10

Barlogie B, 1997, Clin Cancer Res, 3, 2605
Singhal S, 1996, Blood, 88, 611a
Munshi N, 1998, Blood, 92, 98a
10.2307/2281868 · DOI · Paper page
Mantel N, 1966, Cancer Chemother Rep, 50, 163
Figg WD, 1997, Proc Am Soc Clin Oncol, 16, 333a
Fine HA, 1997, Proc Am Soc Clin Oncol, 16, 385a
Long G, 1998, Proc Am Soc Clin Oncol, 17, 181a
Eisen T, 1998, Proc Am Soc Clin Oncol, 17, 441a
Nguyen M, 1997, Int J Oncol, 10, 965

Sorted by citations

Items 201–300 of 1,002

Drug repurposing for breast cancer therapy: Old weapon for new battle
Aggarwal, S., Verma, S. S., Aggarwal, S. S., & Gupta, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.012 · Cited by 172
Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma
Popat, U., Saliba, R. M., Thandi, R. S., Hosing, C. M., Qazilbash, M. H., Anderlini, P. N., Shpall, E. J., McMannis, J. D., Korbling, M. J., Alousi, A. M., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.02.011 · Cited by 168
Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Raimondo, F. D., Azzaro, M. P., Palumbo, G. A., Bagnato, S., Giustolisi, G., Floridia, P. M., Sortino, G., & Giustolisi, R. (2000) · PubMed · Cited by 168
Myeloma of the central nervous system: association with high‐risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations
Fassas, A., Muwalla, F., Berryman, T., Benramdane, R., Joseph, L., Anaissie, E. J., Sethi, R., Desikan, R. K., Siegel, D. S. D., Badros, A. Z., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03401.x · Cited by 167
Self-citation
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations
Mohty, B., Cheikh, J. E., Yakoub‐Agha, I., Moreau, P., Harousseau, J., & Mohty, M. (2010) · Haematologica · doi:10.3324/haematol.2009.012674 · Cited by 172
Focus on multiple myeloma
Mitsiades, C. S., Mitsiades, N., Munshi, N. C., & Anderson, K. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.020 · Cited by 166
Self-citation
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma
Kaufmann, H., Raderer, M., Wöhrer, S., Püspök, A., Bankier, A. A., Zielinski, C. C., Chott, A., & Drach, J. W. (2004) · Blood · doi:10.1182/blood-2004-03-1091 · Cited by 164
Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01121 · Cited by 184
Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma
Barlogie, B., Tricot, G. J. K., van Rhee, F., Angtuaco, E., Walker, R., Epstein, J., Shaughnessy, J. D., Jagannath, S., Bolejack, V., Gurley, J., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06271.x · Cited by 162
Self-citation
Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders
Yamamoto, J., Ito, T., Yamaguchi, Y., & Handa, H. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00116k · Cited by 169
Thalidomide for previously untreated indolent or smoldering multiple myeloma
Rajkumar, S. V., Dispenzieri, A. A., Fonseca, R., Lacy, M., Geyer, S. M., Lust, J., Kyle, R. A., Greipp, P., Gertz, M. A., & Witzig, T. (2001) · Leukemia · doi:10.1038/sj.leu.2402183 · Cited by 163
Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity
Dredge, K. S., Marriott, J. B., Todryk, S. M., Muller, G. W., Chen, R., Stirling, D., & Dalgleish, A. G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.10.4914 · Cited by 163
Angiogenesis in multiple myeloma
Jakob, C., Sterz, J., Zavrski, I., Heider, U., Kleeberg, L., Fleissner, C., Kaiser, M., & Sezer, O. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.02.017 · Cited by 163
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo
Lentzsch, S., LeBlanc, R., Podar, K., Davies, F. E., Lin, B. K., Hideshima, T., Catley, L. P., Stirling, D., & Anderson, K. C. (2003) · Leukemia · doi:10.1038/sj.leu.2402745 · Cited by 162
Myeloma today: Disease definitions and treatment advances
Rajkumar, S. V. (2015) · American Journal of Hematology · doi:10.1002/ajh.24236 · Cited by 163
Anti‐angiogenic drugs: from bench to clinical trials
Quesada, A. R., Muñoz‐Chápuli, R., & Medina, M. Á. (2006) · Medicinal Research Reviews · doi:10.1002/med.20059 · Cited by 159
Multiple myeloma: 2013 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2013) · American Journal of Hematology · doi:10.1002/ajh.23390 · Cited by 158
The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma
García‐Sánz, R., González‐Porras, J. R., Hernández‐Rivas, J. M., Zarzuela, M. P., Sureda, A. M., Barrenetxea, C., Palomera, L., López, R., García, C. G., Alegre, A. M., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403322 · Cited by 159
Treatment options for relapsed and refractory multiple myeloma
Nooka, A. K., Kastritis, E., Dimopoulos, M. A., & Lonial, S. (2015) · Blood · doi:10.1182/blood-2014-11-568923 · Cited by 157
New Drugs for Myeloma
Richardson, P. G. G., Mitsiades, C. S., Schlossman, R. L., Munshi, N. C., & Anderson, K. C. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-664 · Cited by 158
Self-citation
Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics
El-Osta, H. E., & Kurzrock, R. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0212 · Cited by 157
Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers
Begley, C. G., Ashton, M. R., Baell, J. B., Bettess, M. D., Brown, M. P., Carter, B. A., Charman, W. N., Davis, C., Fisher, S., Frazer, I. H., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd5524 · Cited by 164
Thalidomide and its analogues have distinct and opposing effects on TNF-αand TNFR2 during co-stimulation of both CD4+ and CD8+ T cells
Marriott, J. B., Clarke, I., Dredge, K. S., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2002.01954.x · Cited by 155
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications
Jakubı́ková, J., Adamia, S., Kost‐Alimova, M., Klippel, S., Cervi, D. N., Daley, J. F., Cholujová, D., Kong, S., Leiba, M., Blotta, S., et al. (2011) · Blood · doi:10.1182/blood-2010-02-267344 · Cited by 154
Multiple myeloma: biology of the disease
Mahindra, A. K., Hideshima, T., & Anderson, K. C. (2010) · Blood Reviews · doi:10.1016/s0268-960x(10)70003-5 · Cited by 157
The bone-marrow niche in MDS and MGUS: implications for AML and MM
Ghobrial, I. M., Detappe, A., Anderson, K. C., & Steensma, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.197 · Cited by 156
Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2011) · American Journal of Hematology · doi:10.1002/ajh.21913 · Cited by 152
Treatment of Multiple Myeloma: A Comprehensive Review
Kyle, R. A., & Rajkumar, S. V. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.n.056 · Cited by 153
Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy
Cavo, M., Zamagni, E., Cellini, C., Tosi, P., Cangini, D., Cini, M., Valdré, L., Palareti, G., Masini, L., Tura, S., et al. (2002) · Blood · doi:10.1182/blood-2002-06-1674 · Cited by 152
Clinical pharmacokinetics of thalidomide
Teo, S. K., Colburn, W. A., Tracewell, W. G., Kook, K. A., Stirling, D. I., Jaworsky, M. S., Scheffler, M. A., Thomas, S. D., & Laskin, O. L. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443050-00004 · Cited by 150
Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation
Kannt, A., & Đikić, I. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.007 · Cited by 153
Thalidomide metabolism by the CYP2C subfamily.
Ando, Y., Fuse, E., & Figg, W. D. (2002) · PubMed · Cited by 150
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
Anderson, G., Gries, M., Kurihara, N., Honjo, T., Anderson, J., Donnenberg, V. S., Donnenberg, A. D., Ghobrial, I. M., Mapara, M. Y., Stirling, D., et al. (2005) · Blood · doi:10.1182/blood-2005-08-3450 · Cited by 148
Crosstalks between inflammasome and autophagy in cancer
Chung, C., Seo, W., Silwal, P., & Jo, E. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00936-9 · Cited by 149
New insights into role of microenvironment in multiple myeloma
Tricot, G. J. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)00019-2 · Cited by 149
Thalidomide for the treatment of patients with myelodysplastic syndromes
Strupp, C., Germing, U., Aivado, M. A., Misgeld, E., Haas, R. R., & Gattermann, N. (2002) · Leukemia · doi:10.1038/sj.leu.2402330 · Cited by 149
MR imaging of therapy-induced changes of bone marrow
Daldrup-Link, H. E., Henning, T. D., & Link, T. M. (2006) · European Radiology · doi:10.1007/s00330-006-0404-1 · Cited by 148
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II
Shaughnessy, J. D., Tian, E., Sawyer, J. R., McCoy, J., Tricot, G. J. K., Jacobson, J. L., Anaissie, E. J., Zangari, M., Fassas, A., Muwalla, F., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.03948.x · Cited by 148
Self-citation
Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells
Li, H., Hu, J., Wu, S., Wang, L., Cao, X., Zhang, X., Dai, B., Cao, M., Shao, R., Zhang, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6516 · Cited by 149
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
Barwick, B. G., Neri, P. E., Bahlis, N. J., Nooka, A. K., Dhodapkar, M. V., Jaye, D. L., Hofmeister, C. C., Kaufman, J. L., Gupta, V. A., Auclair, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09555-6 · Cited by 147
Self-citation
NF-κB in cancer—a friend turned foe
Ravi, R. K. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.01.003 · Cited by 147
Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma
Sezer, O., Niemöller, K., Eucker, J., Jakob, C., KAUFMANN, O. W., Zavrski, I., Dietel, M., & Possinger, K. (2000) · Annals of Hematology · doi:10.1007/s002770000236 · Cited by 147
Obesity and the Risk for Cardiovascular Disease
Rashid, M. N., Fuentes, F., Touchon, R. C., & Wehner, P. S. (2003) · Preventive Cardiology · doi:10.1111/j.1520-037x.2003.01358.x · Cited by 146
Tolerability and Efficacy of Thalidomide for the Treatment of Patients with Light Chain–Associated (AL) Amyloidosis
Seldin, D. C., Choufani, E. B., Dember, L. M., Wiesman, J. F., Berk, J. L., Falk, R. H., O’Hara, C., Fennessey, S. A., Finn, K. T., Wright, D. G., et al. (2003) · Clinical Lymphoma · doi:10.3816/clm.2003.n.005 · Cited by 146
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.
Hayashi, T., Hideshima, T., Akiyama, M., Richardson, P. G. G., Schlossman, R. L., Chauhan, D., Munshi, N. C., Waxman, S., & Anderson, K. C. (2002) · PubMed · Cited by 145
Self-citation
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy
Baz, R., Walker, E., Karam, M. A., Choueiri, T. K., Jawde, R. M. A., Bruening, K., Reed, J., Faiman, B. M., Ellis, Y., Brand, C., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl313 · Cited by 143
Self-citation
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
Chanan-Khan, A. A., Swaika, A., Paulus, A., Kumar, S. K., Mikhael, J. R., Rajkumar, S. V., Dispenzieri, A. A., & Lacy, M. Q. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.38 · Cited by 144
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2012) · American Journal of Hematology · doi:10.1002/ajh.22237 · Cited by 144
Degrons in cancer
Mészáros, B., Kumar, M., Gibson, T. J., Uyar, B., & Dosztányi, Z. (2017) · Science Signaling · doi:10.1126/scisignal.aak9982 · Cited by 147
Anti-angiogenic therapy: Rationale, challenges and clinical studies
Longo, R., Sarmiento, R., Fanelli, M., Capaccetti, B., Gattuso, D., & Gasparini, G. (2002) · Angiogenesis · doi:10.1023/a:1024532022166 · Cited by 143
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma
Dimopoulos, M. A., Hamilos, G., Zomas, A., Gika, D., Efstathiou, E., Grigoraki, V., Poziopoulos, C., Xilouri, I., Zorzou, M. P., Anagnostopoulos, N. I., et al. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200326 · Cited by 144
Old friends in new guise: repositioning of known drugs with structural bioinformatics
Haupt, V. J., & Schroeder, M. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr011 · Cited by 142
Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04–IFCT 00-01
Pujol, J. L., Breton, J. L., Gervais, R., Tanguy, M., Quoix, É., David, P., Janicot, H., Westeel, V., Gameroff, S., Genève, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8109 · Cited by 143
Therapy for Relapsed Multiple Myeloma
Dingli, D., Ailawadhi, S., Bergsagel, P. L., Buadi, F. K., Dispenzieri, A. A., Fonseca, R., Gertz, M. A., Gonsalves, W. I., Hayman, S. R., Kapoor, P., et al. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.01.003 · Cited by 144
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma
Mai, E. K., Bertsch, U., Dürig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A. T., Schurich, B., Hielscher, T., et al. (2015) · Leukemia · doi:10.1038/leu.2015.80 · Cited by 145
Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience
Şimşek, C., Esin, E., & Yalçın, Ş. (2019) · Journal of Oncology · doi:10.1155/2019/5483791 · Cited by 141
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers
Bartlett, J. B., Michael, A., Clarke, I., Dredge, K. S., Nicholson, S., Kristeleit, H., Polychronis, A., Pandha, H. S., Muller, G. W., Stirling, D., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601579 · Cited by 141
Self-citation
Thalidomide: Emerging Role in Cancer Medicine
Richardson, P. G. G., Hideshima, T., & Anderson, K. C. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104043 · Cited by 141
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma
Palumbo, A., Bertola, A., Falco, P., Rosato, R., Cavallo, F., Giaccone, L., Bringhen, S., Musto, P., Pregno, P., Caravita, T., et al. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200403 · Cited by 140
The myelodysplastic syndrome(s): a perspective and review highlighting current controversies
Steensma, D. P., & Tefferi, A. (2003) · Leukemia Research · doi:10.1016/s0145-2126(02)00098-x · Cited by 140
VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma
Pineda-Roman, M., Zangari, M., van Rhee, F., Anaissie, E., Szymonifka, J., Hoering, A., Petty, N., Crowley, J., Shaughnessy, J., Epstein, J., et al. (2008) · Leukemia · doi:10.1038/leu.2008.99 · Cited by 139
Self-citation
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis
Dispenzieri, A. A., Lacy, M. Q., Rajkumar, S. V., Geyer, S. M., Witzig, T. E., Fonseca, R., Lust, J. A., Greipp, P. R., Kyle, R. A., & Gertz, M. A. (2003) · Amyloid · doi:10.3109/13506120309041743 · Cited by 139
Multiple Myeloma
Laubach, J. P., Richardson, P. G. G., & Anderson, K. C. (2010) · Annual Review of Medicine · doi:10.1146/annurev-med-070209-175325 · Cited by 140
Thalidomide induces γ-globin gene expression through increased reactive oxygen species–mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis
Aerbajinai, W., Zhu, J., Gao, Z., Chin, K., & Rodgers, G. P. (2007) · Blood · doi:10.1182/blood-2007-01-065201 · Cited by 139
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Approach to the treatment of multiple myeloma: a clash of philosophies
Rajkumar, S. V., Gahrton, G., & Bergsagel, P. L. (2011) · Blood · doi:10.1182/blood-2011-06-297853 · Cited by 138
Glutamic Acid and Its Derivatives: Candidates for Rational Design of Anticancer Drugs
Ali, I., Wani, W. A., Haque, A., & Saleem, K. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.62 · Cited by 137
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma
Kropff, M. H., Lang, N., Bisping, G., Dominé, N., Innig, G., Hentrich, M., Mitterer, M., Südhoff, T., Fenk, R. R., Straka, C., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04473.x · Cited by 137
Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
Lee, S. M., Woll, P. J., Rudd, R., Ferry, D. R., O'Brien, M. E. R., Middleton, G., Spiro, S. G., James, L. E., Ali, K., Jitlal, M., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp200 · Cited by 135
Waldenström macroglobulinaemia
Fonseca, R., & Hayman, S. R. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06724.x · Cited by 136
Human Pituitary Tumor-Transforming Gene Induces Angiogenesis1
Ishikawa, H., Heaney, A. P., Yu, R., Horwitz, G. A., & Melmed, S. K. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7184 · Cited by 135
Impact of complete remission with intensive therapy in patients with responsive multiple myeloma
Alexanian, R., Weber, D., Giralt, S. A., Dimopoulos, M. A., Delasalle, K. B., Smith, T., & Champlin, R. E. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703035 · Cited by 135
Cancer multidrug resistance: a review of recent drug discovery research.
Liscovitch, M., & Lavie, Y. (2002) · PubMed · Cited by 134
Extramedullary multiple myeloma escapes the effect of thalidomide.
Rosiñol, L., Cibeira, M. T., Bladé, J., Esteve, J., Aymerich, M., Rozman, M., Segarra, M., Cid, M. C., Filella, X., & Montserrat, E. (2004) · PubMed · Cited by 134
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies
Barlogie, B., Tricot, G. J. K., Rasmussen, E., Anaissie, E. J., van Rhee, F., Zangari, M., Fassas, A., Hollmig, K. A., Pineda‐Roman, M., Shaughnessy, J. D., et al. (2005) · Blood · doi:10.1182/blood-2005-10-4084 · Cited by 136
Self-citation
Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma
Kumar, S. K., Gertz, M. A., Dispenzieri, A. A., Lacy, M. Q., Geyer, S. M., Iturria, N. L., Fonseca, R., Hayman, S. R., Lust, J. A., Kyle, R. A., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.34 · Cited by 134
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer
Figg, W. D., Arlen, P., Gulley, J. L., Fernandez, P., Noone, M., Fedenko, K., Hamilton, M., Parker, C., Kruger, E. A., Pluda, J., et al. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90157-5 · Cited by 134
Targeting the Tumor Microenvironment: Focus on Angiogenesis
Fan, F., Schimming, A., Jaeger, D., & Podar, K. (2011) · Journal of Oncology · doi:10.1155/2012/281261 · Cited by 139
A Novel Anticancer Effect of Thalidomide: Inhibition of Intercellular Adhesion Molecule-1–Mediated Cell Invasion and Metastasis through Suppression of Nuclear Factor-κB
Lin, Y.-C., Shun, C., Wu, M., & Chen, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1393 · Cited by 132
Thalidomide in cancer
Singhal, S., & Mehta, J. (2002) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(01)00146-9 · Cited by 132
Self-citation
NF-κB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen
deGraffenried, L. A., Chandrasekar, B., Friedrichs, W. E., Donzis, E. J., Silva-Fisher, J., Hidalgo, M. M., Freeman, J. W., & Weiss, G. R. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh232 · Cited by 132
Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back
Bianchi, G., & Anderson, K. C. (2014) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21252 · Cited by 135
Artificial Intelligence in Drug Discovery: A Comprehensive Review of Data-driven and Machine Learning Approaches
Kim, H., Kim, E., Lee, I., Bae, B., Park, M., & Nam, H. (2020) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-020-0049-y · Cited by 146
Evaluation of microvascular density in tumors: pro and contra.
Nico, B., Benagiano, V., Mangieri, D., Maruotti, N., Vacca, A., & Ribatti, D. (2008) · PubMed · doi:10.14670/hh-23.601 · Cited by 132
Phase II Trial of Thalidomide for Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Berg, W. J., Ginsberg, M. S., Russo, P., Vuky, J., Yu, R., Bacik, J., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.302 · Cited by 131
Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide
Bjorklund, C. C., Ma, W., Wang, Z.-Q., Davis, R. E., Kuhn, D. J., Kornblau, S. M., Wang, M., Shah, J. J., & Orlowski, R. Z. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.180208 · Cited by 130
Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study
Tsakiris, D., Stel, V. S., Finne, P., Fraser, E., Heaf, J. G., Meester, J. D., Schmaldienst, S., Dekker, F. W., Verrina, E. E., & Jager, K. J. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp679 · Cited by 130
Adverse effects of thalidomide administration in patients with neoplastic diseases
Dimopoulos, M. A., & Eleutherakis-Papaiakovou, V. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.03.040 · Cited by 130
Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma
Vacca, A., Scavelli, C., Montefusco, V., Pietro, G. D., Neri, A., Mattioli, M., Bicciato, S., Nico, B., Ribatti, D., Dammacco, F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.723 · Cited by 130
SWEETLEAD: an In Silico Database of Approved Drugs, Regulated Chemicals, and Herbal Isolates for Computer-Aided Drug Discovery
Novick, P. A., Ortiz, O. F., Poelman, J., Abdulhay, A., & Pande, V. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079568 · Cited by 130
Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center
Damaj, G. L., Mohty, M., Vey, N., D’Incan, E., Bouabdallah, R., Faucher, C., Stoppa, A., & Gastaut, J. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00331.x · Cited by 129
Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives
Dimopoulos, M. A., Anagnostopoulos, A., & Weber, D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.200 · Cited by 129
Bortezomib: an effective agent in extramedullary disease in multiple myeloma
Rosiñol, L., Cibeira, M. T., Uriburu, C., Yantorno, S., Salamero, O., Bladé, J., & Montserrat, E. (2006) · European Journal Of Haematology · doi:10.1111/j.0902-4441.2005.t01-1-ejh2462.x · Cited by 128
Continued survival gains in recent years among critically ill myeloma patients
Peigne, V., Rusínová, K., Karlin, L., Darmon, M., Fermand, J., Schlemmer, B., & Azoulay, É. (2008) · Intensive Care Medicine · doi:10.1007/s00134-008-1320-4 · Cited by 129
Updated and New Perspectives on Diagnosis, Prognosis, and Therapy of Malignant Pheochromocytoma/Paraganglioma
Parenti, G., Zampetti, B., Rapizzi, E., Ercolino, T., Giaché, V., & Mannelli, M. (2012) · Journal of Oncology · doi:10.1155/2012/872713 · Cited by 126
Discovery of E3 Ligase Ligands for Target Protein Degradation
Lee, J., Lee, Y., Jung, Y. M., Park, J. H., Yoo, H. S., & Park, J. (2022) · Molecules · doi:10.3390/molecules27196515 · Cited by 131
Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme
Marx, G. M., Pavlakis, N., McCowatt, S., Boyle, F. M., Levi, J. A., Bell, D. R., Cook, R., Biggs, M. T., Little, N., & Wheeler, H. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1012554328801 · Cited by 127
Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma
Bisping, G., Leo, R., Wenning, D., Dankbar, B., Padró, T., Kropff, M. H., Scheffold, C., Kröger, M., Mesters, R. M., Berdel, W. E., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2907 · Cited by 127
Treatment of Waldenstrom’s Macroglobulinemia With Thalidomide
Dimopoulos, M. A., Zomas, A., Viniou, N. A., Grigoraki, V., Galani, E. P., Matsouka, C., Economou, O., Anagnostopoulos, N. I., & Panayiotidis, P. G. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3596 · Cited by 127
Neuropathy in multiple myeloma treated with thalidomide
Plasmati, R., Pastorelli, F., Cavo, M., Petracci, E., Zamagni, E., Tosi, P., Cangini, D., Tacchetti, P., Salvi, F., Bartolomei, I., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267271.18475.fe · Cited by 126

Authors: Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeldis, J., Siegel, D., Crowley, J., & Barlogie, B.
Affiliations: University of South Carolina (US)
University of Arkansas for Medical Sciences (US)
Rockefeller University (US)
ORCID: Singhal, Seema
Desikan, Raman
Roberson, Paula
Munshi, Nikhil
Dhodapkar, Madhav
Zeldis, Jerome
Siegel, David
Barlogie, Bart
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1999-11-18
Volume: 341
Issue: 21
Pages: 1565-1571
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199911183412102
OpenAlex: W2316160054
Cited by: 2,575
References: 35
Citations by year: 2026: 27 · 2025: 41 · 2024: 48 · 2023: 48 · 2022: 69 · 2021: 73 · 2020: 62 · 2019: 67 · 2018: 56 · 2017: 62 · 2016: 69 · 2015: 75 · 2014: 76 · 2013: 102 · 2012: 89
FWCI: 69.79
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P01CA055819, CA-55819)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords: thalidomide, multiple myeloma, refractory multiple myeloma, anti-angiogenic therapy, Bence Jones protein, microvessel density, event-free survival, overall survival, adverse effects
MeSH terms: Bence Jones Protein, Bone Marrow, Bone Marrow Examination, Drug Administration Schedule, Female, Humans, Male, Microcirculation, Middle Aged, Multiple Myeloma, Myeloma Proteins, Recurrence, Remission Induction, Thalidomide, Multivariate Analysis, Survival Analysis, Disease Progression, Angiogenesis Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks